HEXAXIM CONJUGATE VACCINE

Indications

• Diphtheria infection
• Respiratory diphtheria
• Cutaneous diphtheria
• Prevention of diphtheria in exposed individuals

Dosage

Adults: Consult local guidelines or the BNF for appropriate dosing for diphtheria treatment.

Mechanism of action

Corynebacterium diphtheriae produces a potent exotoxin that inhibits protein synthesis in host cells by inactivating elongation factor-2 (EF-2) through ADP-ribosylation. This leads to cell death and contributes to the local tissue damage and systemic effects observed in diphtheria. The diphtheria toxoid vaccine stimulates the immune system to produce antibodies against the toxin, thereby preventing the disease.

Pharmacodynamics

The clinical effects of diphtheria are primarily due to the diphtheria toxin, which causes local inflammation and tissue necrosis in the throat, leading to the characteristic pseudomembrane formation. Systemically, the toxin can lead to myocarditis, peripheral neuropathy, and other complications. Antibiotics help to control the infection and reduce toxin production, while antitoxin neutralizes the circulating toxin.

Pharmacokinetics

The pharmacokinetics of diphtheria antitoxin and antibiotics varies. Diphtheria antitoxin is administered intravenously or intramuscularly, with effects seen rapidly as it neutralizes circulating toxin. Antibiotics like penicillin and erythromycin are absorbed from the gastrointestinal tract and distributed throughout the body, with renal excretion as the primary route of elimination. The half-lives of these antibiotics typically range from 1 to 3 hours, necessitating multiple doses for effective treatment.

Contra-indications

• Severe allergic reaction to diphtheria toxoid or any component of the vaccine

Adverse effects

• Local reaction at the injection site
• Fever
• Fatigue
• Malaise
• Headache
• Nausea
• Irritability
• Anaphylaxis (rare)

Interactions

• Live attenuated vaccines should not be administered simultaneously with diphtheria vaccine; separate by at least 4 weeks
• Immunosuppressive therapies may reduce the effectiveness of the vaccine

Precautions

• History of moderate or severe acute illness
• History of allergic reactions to vaccines
• Caution in individuals with a history of Guillain-Barré syndrome

Pregnancy

Diphtheria vaccine is recommended during pregnancy if there is a risk of exposure to the disease, as it provides passive immunity to the newborn.

Breast-feeding

The vaccine is considered safe during breastfeeding.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Bronchitis

Dosage

Children: Refer to specific antibiotic guidelines for pediatric dosing based on the type and severity of the infection caused by Haemophilus species.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of the infection caused by Haemophilus species.

Mechanism of action

H. influenzae adheres to epithelial cells via pili and other surface structures, allowing colonization of the nasopharynx. The encapsulated strains evade phagocytosis due to their polysaccharide capsule, which inhibits opsonization and complement activation. This leads to the systemic spread of the bacteria and can result in severe infections if not effectively treated.

Pharmacodynamics

H. influenzae can produce various virulence factors, including polysaccharide capsules, endotoxins, and enzymes that contribute to its pathogenicity. The bacteria can resist the effects of certain antibiotics through mechanisms such as beta-lactamase production, which hydrolyzes beta-lactam antibiotics, rendering them ineffective. The host's immune response is often inadequate to clear the infection due to the bacterium's ability to evade immune detection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat H. influenzae infections vary based on the specific drug. Common antibiotics include ampicillin and ceftriaxone. The absorption, distribution, metabolism, and excretion depend on the antibiotic used. For example, ampicillin is well absorbed from the gastrointestinal tract, widely distributed in body tissues and fluids, and eliminated primarily via renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Rash
• Irritability
• Anaphylaxis (rare)

Precautions

• Caution in patients with a history of severe allergic reactions
• Monitor for signs of anaphylaxis after administration
• Assess for underlying immunocompromised conditions

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral tablets

Indications

• Acute viral hepatitis
• Chronic hepatitis B
• Chronic hepatitis C
• Autoimmune hepatitis
• Alcoholic hepatitis
• Non-alcoholic fatty liver disease

Dosage

Children: Paediatric dosing also varies significantly based on the specific condition and medication. As with adult dosing, it is important to refer to the BNF for Children for specific recommendations.

Adults: Dosing for adult patients varies widely depending on the specific antiviral agent used and the type of hepatitis. It is essential to refer to specific guidelines or the BNF for precise dosing.

Mechanism of action

In viral hepatitis, the viruses typically enter liver cells and replicate, leading to cellular injury and inflammation. The immune response to the infection contributes to liver damage. Antiviral therapies aim to inhibit viral replication, either by directly targeting viral enzymes or by modulating the host immune response.

Pharmacodynamics

The pharmacodynamics of antiviral agents used in hepatitis treatment involve the inhibition of viral replication, reduction of viral load, and improvement of liver function. This can lead to a decrease in serum liver enzymes (ALT and AST) and an improvement in clinical symptoms. In chronic hepatitis B and C, sustained virologic response is the goal, indicating effective viral suppression.

Pharmacokinetics

The pharmacokinetics of antiviral medications used for hepatitis can vary significantly depending on the specific drug. Generally, these agents are absorbed from the gastrointestinal tract, metabolized in the liver, and excreted through urine or feces. The half-lives of these drugs can vary, influencing dosing schedules.

Pregnancy

Consult medical guidelines as hepatitis can pose risks during pregnancy; specific management depends on the type of hepatitis.

Breast-feeding

Consult healthcare providers, as the safety of certain hepatitis medications during breastfeeding varies.

Storage

Store in a cool, dry place away from direct sunlight; specific storage conditions may vary based on the medication used.

Indications

• Influenza virus infection
• Prophylaxis of influenza in high-risk populations
• Treatment of suspected or confirmed influenza in children and adults

Dosage

Children: Refer to the specific antiviral medication's product information for dosing guidance.

Adults: Refer to the specific antiviral medication's product information for dosing guidance.

Mechanism of action

Antiviral medications targeting influenza, such as neuraminidase inhibitors (e.g., oseltamivir), work by inhibiting the neuraminidase enzyme on the surface of the virus. This inhibition prevents the release of new viral particles from infected cells, thus limiting the spread of the virus within the respiratory tract.

Pharmacodynamics

The pharmacodynamic effects of antiviral agents against influenza include a reduction in the severity and duration of symptoms, as well as a decrease in the viral load. Neuraminidase inhibitors are most effective when administered within 48 hours of the onset of symptoms, as they can significantly reduce the duration of illness and the risk of complications.

Pharmacokinetics

Antivirals such as oseltamivir are administered orally and are quickly absorbed from the gastrointestinal tract. The drug is converted to its active form, oseltamivir carboxylate, primarily in the liver. It has a half-life of approximately 6 to 10 hours and is predominantly eliminated via the kidneys. Patients with renal impairment may require dose adjustments to avoid toxicity.

Pregnancy

Consult healthcare provider for risks and benefits.

Breast-feeding

Consult healthcare provider for risks and benefits.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Prevention of pertussis through vaccination
• Treatment of pertussis in infected individuals

Dosage

Children: For treatment of pertussis in children, refer to the BNF for Children for appropriate dosing based on age and weight.

Adults: For treatment of pertussis, refer to guidelines as specific antibiotic doses may vary based on the agent used and patient factors.

Mechanism of action

Bordetella pertussis adheres to the ciliated epithelial cells of the nasopharynx and produces several virulence factors, including pertussis toxin, which disrupts normal cellular signaling and immune responses. This leads to the characteristic symptoms of the disease, including paroxysmal coughing due to the inhibition of ciliary function and increased mucus production.

Pharmacodynamics

The pathophysiology of pertussis involves the inflammatory response triggered by the presence of the bacterium and its toxins. The pertussis toxin has multiple effects, including increasing adenylate cyclase activity, which elevates cyclic AMP levels in host cells, leading to altered immune responses. This results in the characteristic cough due to irritation of the airway and bronchoconstriction.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis is not applicable as it is a bacterium rather than a drug. However, the immune response, once triggered by either natural infection or vaccination, involves the production of antibodies that provide long-term protection against reinfection. Antibiotics, when prescribed, are absorbed systemically, metabolized in the liver, and excreted primarily through the kidneys.

Adverse effects

• Cough
• Fever
• Vomiting
• Fatigue
• Nasal congestion

Precautions

• Use with caution in patients with a history of respiratory disorders
• Monitor for secondary bacterial infections

Pregnancy

The safety of pertussis vaccination during pregnancy is generally considered acceptable; however, it is essential to consult healthcare providers for individualized recommendations.

Breast-feeding

Vaccination is considered safe during breastfeeding, but consultation with healthcare providers is advisable.

Storage

Store in a cool, dry place away from direct sunlight. Ensure that the vaccine is not frozen.

Formulations

• Pertussis vaccine (injectable suspension)

Indications

• Prevention of poliomyelitis infection
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for specific dosages and recommendations for vaccination schedules.

Adults: Refer to specific vaccination guidelines for adults, as dosages may vary based on risk factors and prior vaccination history.

Mechanism of action

Poliovirus enters the body through the oral route, replicating in the oropharynx and gastrointestinal tract before spreading to the central nervous system via the bloodstream. Once inside the CNS, the virus selectively infects motor neurons in the anterior horn of the spinal cord, leading to cell lysis and resulting in muscle weakness or paralysis. The immune response to the virus contributes to inflammation and further neuronal damage.

Pharmacodynamics

The poliovirus's pathogenicity is primarily due to its ability to evade the host's immune response and its selective neurotropism. The destruction of motor neurons leads to flaccid paralysis, with recovery possible in some cases as the motor neurons may regenerate. The severity of the disease correlates with the extent of neuronal involvement, which can vary widely among individuals.

Pharmacokinetics

Poliovirus is an RNA virus that does not undergo traditional pharmacokinetic processes as it is not treated with drugs. Instead, the prevention of polio relies on vaccination strategies. The inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV) are used to induce immunity. After administration, the vaccines promote the development of antibodies against the virus without causing disease.

Contra-indications

• Hypersensitivity to the vaccine component
• Severe immunodeficiency
• Acute febrile illness

Adverse effects

• Pain at injection site
• Fever
• Fatigue
• Headache
• Nausea
• Allergic reactions

Interactions

• Immunosuppressive therapies may reduce vaccine efficacy
• Concomitant administration with other vaccines may affect immune response

Precautions

• Use with caution in individuals with moderate to severe acute illness
• Consider history of allergic reactions
• Monitor for signs of anaphylaxis after administration

Pregnancy

Poliomyelitis vaccination is generally considered safe during pregnancy, but consult a healthcare professional.

Breast-feeding

The vaccine is considered safe for breastfeeding mothers.

Storage

Store at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine